L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism
- PMID: 4885744
L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism
Similar articles
-
[Effects of L-dopa and stereotaxic surgery in Parkinsonism].No To Shinkei. 1970 Sep;22(9):1103-8. No To Shinkei. 1970. PMID: 4918927 Clinical Trial. Japanese. No abstract available.
-
[Use of L-DOPA in the therapy of parkinsonism].Rass Int Clin Ter. 1971 Feb 28;51(4):193-221. Rass Int Clin Ter. 1971. PMID: 4930734 Clinical Trial. Italian. No abstract available.
-
[Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].No To Shinkei. 1970 Sep;22(9):1091-101. No To Shinkei. 1970. PMID: 5536082 Japanese. No abstract available.
-
[Long term treatment of a parkinsonism with l-dopa].Tidsskr Nor Laegeforen. 1973 Oct 10;93(28):2111-3. Tidsskr Nor Laegeforen. 1973. PMID: 4590069 Review. Norwegian. No abstract available.
-
[Current treatment of Parkinson syndrome with L-dopa].Pol Tyg Lek. 1972 May 22;27(21):798-800. Pol Tyg Lek. 1972. PMID: 4555002 Review. Polish. No abstract available.
Cited by
-
One to two year treatment of Parkinson's disease with levodopa.Calif Med. 1971 May;114(5):7-14. Calif Med. 1971. PMID: 5087881 Free PMC article.
-
Treatment of Parkinsonism with Laevo-dopa.Br Med J. 1970 Feb 7;1(5692):331-7. doi: 10.1136/bmj.1.5692.331. Br Med J. 1970. PMID: 4906702 Free PMC article. Clinical Trial.
-
Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.Z Neurol. 1972;202(1):1-20. doi: 10.1007/BF00316422. Z Neurol. 1972. PMID: 4114458 Clinical Trial. No abstract available.
-
Assessment of autonomic function in patients with a Parkinsonian syndrome.Br Med J. 1971 Oct 9;4(5779):80-4. doi: 10.1136/bmj.4.5779.80. Br Med J. 1971. PMID: 5097425 Free PMC article.
-
Levodopa therapy of patients with Parkinsonism and heart disease.Br Med J. 1972 Aug 26;3(5825):512-4. doi: 10.1136/bmj.3.5825.512. Br Med J. 1972. PMID: 4538397 Free PMC article.